Veri MedTech Holdings, Inc. S-1/Aamended IPO prospectus

Executive Summary

Veri Medtech connects patients with physicians for medical-cannabis certifications, earning consultation-processing fees and annual-renewal revenue. Revenue fell 34.9% to $10.8M in FY2025, with a $(2.32)M net loss; H1 2026 revenue declined another 26.7%, while lower compensation and marketing spending narrowed losses. The unpriced, all-primary offering assumes $4.00 per share: $15.0M gross proceeds, an implied $47.0M common-equity valuation and a 31.9% stake for offering buyers before additional dilution. At 4.33× FY2025 revenue, investors are funding a turnaround and early-stage healthcare expansion—not a demonstrated growth business—with severe pre-offering liquidity pressure, founder voting control and substantial potential equity awards.

The Offering

• Size and implied valuation: 3,750,000 new common shares at an assumed $4.00 produce $15.0M gross proceeds; 11,750,004 post-offering common shares imply $47.0M market capitalization, 31.9% ownership for buyers and 4.33× FY2025 revenue. Including 187,500 underwriter warrants gives 11,937,504 common shares, $47.8M valuation and 31.4% buyer ownership. Including the separate potential 24,000,000 executive performance shares gives 35,937,504 shares and $144M valuation if granted and earned; the disclosures also describe IPO-contingent executive options, making ultimate dilution uncertain.
• Terms and listing: This preliminary offering is unpriced; $4.00 is an assumption, not a final price or range. Network 1 Financial Securities leads underwriting. A 45-day option covers 562,500 additional shares, raising gross proceeds to $17.3M if exercised fully. Completion requires Nasdaq Capital Market approval under VRHI; shares currently trade on OTCID.
• Proceeds and costs: The company receives estimated net proceeds of $11.9M, or $14.0M with full over-allotment; there are no secondary sales. Base allocations are $2.55M operations, $0.200M accounting support, $2.80M marketing/development, $2.00M acquisitions and $4.40M working-capital reserves. Management can reallocate funds. Base offering costs total $3.05M, including a 7% underwriting discount and 2% finance fee.
• Dilution: Each $4.00 share is backed by $0.78 of net tangible assets after the offering—a $3.22 gap. Existing holders’ backing rises from $(0.34) to $0.78 per share; buyers supply the capital repairing the deficit.
• Capitalization: “After IPO” below assumes the base offering’s net proceeds are added to the 6/30/2026 balance sheet, without over-allotment or debt repayment. Cash rises by $11.9M and equity turns positive; no preferred-stock conversion drives this change.
• Capital allocation and resale: A discretionary 3,000,000-share repurchase authorization equals 80% of the base offering, potentially competing with growth and liquidity needs. Officers, directors and holders above 5% face 180-day lock-ups after the final prospectus date; restricted shares may become sale-eligible 12 months after registration effectiveness, subject to applicable restrictions.

Key Financial Highlights

$M unless stated; annual figures audited, interim figures unaudited. Balance-sheet columns are historical except “After IPO.”

• Revenue mechanism: State consultation restrictions drove FY2025 contraction; reduced advertising drove further interim volume declines. Stable gross margins have not offset lost sales.
• Loss improvement: H1 compensation fell $1.30M as restricted awards finished vesting and staffing declined; narrower losses therefore do not demonstrate demand recovery.
• Cash-flow quality: FY2025 OCF benefited from $2.38M noncash stock-based compensation and increased payables/related-party balances. H1 2026 stock-based compensation fell to $0.109M; positive OCF still coincided with declining cash after financing repayments.
• Deficit and runway: The $5.34M accumulated deficit explains negative equity, not preferred-stock conversion accounting; total liabilities substantially exceed indebtedness. Management estimated only 3–6 months of operating runway and $2.00M minimum funding for 12 months.
• Insider funding: At 6/30/2026, officer advances were $0.342M, related-party unpaid rent $0.172M, and unpaid officer salaries/taxes $1.09M—evidence that liquidity depends partly on insiders deferring payment.

Business Model and Growth Drivers

• Core economics: Patients pay ≈$100.00–$200.00 per certification or renewal. Revenue is earned after consultation and the physician’s decision; physician and payment-processing fees are principal direct costs. Medical-cannabis evaluations generated virtually all interim revenue.
• Volume indicators: Successful paid approvals fell from ≈101,000 in FY2024 to ≈71,000 in FY2025, then from ≈40,200 to ≈29,600 across the comparable first halves. Revenue per paid subscriber was ≈$151.00 in H1 2026 vs ≈$152.00, confirming predominantly volume-driven contraction.
• Expansion strategy: DosePop proposes prescription and wellness subscriptions cross-sold to the legacy patient base. Its soft launch generated ≈$0.024M revenue and ≈$0.005M recurring monthly revenue; Sky Clinics had no operations or revenue. These initiatives offer diversification but have not demonstrated material scale.
• Acquisition engine: The $3.00M MarijuanaDoctors.com acquisition expanded lead generation and the physician network. Management plans further acquisitions, but the offering’s acquisition allocation has no committed transactions.

Governance and Control

• Founder control: Joshua Green and Samuel Adetunji retain 52.0% of post-offering common shares. Their 100 Series A preferred shares collectively command 80% of voting power, plus common-share votes, insulating control from dilution.
• Governance implementation: The company expects controlled-company status but intends not to use Nasdaq governance exemptions. Three independent nominees join upon registration effectiveness; committees had held no meetings, so oversight remains newly established.
• Compensation and dilution: Each founder received $2.21M FY2025 compensation. The 50,000,000-share incentive reserve exceeds four times base post-offering shares; it is authorization, not outstanding awards. Separate disclosures describe up to 24,000,000 performance shares and IPO-contingent options, requiring clarification of overlap before assessing dilution.

Risk Assessment

• Audit, controls and solvency: The auditor raised going-concern doubt, and insufficient accounting staffing caused a material weakness; the $2.46M working-capital deficit makes successful financing critical.
• Regulation: Florida’s in-person consultation requirement already damaged revenue; similar restrictions, recreational legalization or federal cannabis constraints could further reduce certification demand.
• Customer acquisition: Dependence on digital advertising exposes patient volumes to platform restrictions and acquisition costs; reduced marketing already coincided with falling approvals.
• Technology and privacy: Reliance on Amazon Web Services and sensitive patient data creates outage, breach and compliance exposure that could interrupt services and damage renewals.
• Control and dilution: Founder voting dominance limits minority influence, while large equity authorizations and conditional awards can materially dilute economic ownership.
• Valuation and execution: Paying 4.33× shrinking FY2025 revenue requires core demand stabilization and successful commercialization of DosePop, whose initial revenue is minimal.
• Key personnel: Dependence on founders and other key employees means departures could disrupt clinical relationships, operating execution and the expansion strategy.

Investor Actionables

• First report after listing: Watch approvals, revenue per subscriber and marketing spending together; recovery should reflect sustainable patient demand rather than spending alone.
• Cash deployment: Track operating cash flow, overdue insider balances and acquisition/repurchase spending; proceeds should establish durable liquidity rather than merely defer another financing.
• Governance and dilution: Seek clarification of executive award overlap, accounting-control remediation and the final lock-up timetable before treating the headline share count as durable.